Literature DB >> 6797762

Heterozygote detection of type I Gaucher disease using blood platelets.

S Nakagawa, S Kumin, G Sachs, H M Nitowsky.   

Abstract

This report describes a reliable and reproducible method for the identification of carriers of Type I Gaucher disease using blood platelets as the source of beta-glucosidase and 4-methylumbelliferyl-beta-D-glucoside as substrate. Platelet lysates have at least two identifiable beta-glucosidase activities with the synthetic substrate. One is maximally active at pH 5.0 in the absence of sodium taurocholate and the other at pH 5.6 in the presence of taurocholate. In platelets of Gaucher homozygotes and heterozygotes, the beta-glucosidase activity at pH 5.6 with the bile salt is reduced whereas the activity at pH 5.0 is the same in non-carriers, carriers and affected patients. In addition to differences in specific activity, the ratio of beta-hexosaminidase to beta-glucosidase activities is a useful parameter in the evaluation of the carrier state. Since carriers have normal activity of hexosaminidase and a reduced activity of beta-glucosidase, their mean activity ratio is about 70% higher than in non-carriers. Therefore we propose that the specific activity of beta-glucosidase at pH 5.6 in the presence of sodium taurocholate with the ratio of beta-hexosaminidase to beta-glucosidase serve as useful and reliable indices in the evaluation of the carrier state for Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6797762     DOI: 10.1016/0009-8981(82)90231-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Elevation of serum beta-hexosaminidase and alpha-D-mannosidase in type 2 Gaucher disease: a clinical and biochemical study.

Authors:  D Chitayat; S Nakagawa; R W Marion; G S Sachs; S Shinnar; J F Llena; H M Nitowsky
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

2.  A molecular analysis of the GBA gene in Caucasian South Africans with Parkinson's disease.

Authors:  Melinda Barkhuizen; David G Anderson; Francois H van der Westhuizen; Anne F Grobler
Journal:  Mol Genet Genomic Med       Date:  2017-02-08       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.